Short Interest in Talphera, Inc. (NASDAQ:TLPH) Drops By 49.0%

Posted by Scott Moore on Jan 16th, 2025

Talphera, Inc. (NASDAQ:TLPH – Get Free Report) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 30,500 shares, a decline of 49.0% from the December 15th total of 59,800 shares. Based on an average daily volume of 111,000 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the shares of the company are sold short.

Talphera Stock Up 6.8 %

TLPH stock traded up $0.04 during midday trading on Thursday, reaching $0.62. The company had a trading volume of 60,294 shares, compared to its average volume of 96,759. The stock has a 50 day moving average price of $0.67 and a 200 day moving average price of $0.83. The firm has a market capitalization of $10.56 million, a PE ratio of -0.90 and a beta of 0.28. Talphera has a fifty-two week low of $0.50 and a fifty-two week high of $1.61.

Wall Street Analysts Forecast Growth

Separately, Maxim Group raised shares of Talphera to a “strong-buy” rating in a report on Friday, November 8th.

Check Out Our Latest Research Report on Talphera

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Talphera stock. Nantahala Capital Management LLC purchased a new position in shares of Talphera, Inc. (NASDAQ:TLPH – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned about 11.73% of Talphera as of its most recent filing with the Securities & Exchange Commission. 37.67% of the stock is owned by institutional investors.

About Talphera

(Get Free Report)

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.